Inhibition of ANGPTL3 by evinacumab leads to which effect?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Inhibition of ANGPTL3 by evinacumab leads to which effect?

Inhibiting ANGPTL3 releases the brakes on lipid breakdown by lipoprotein lipase (LPL) and endothelial lipase (EL). Evinacumab blocks ANGPTL3, so LPL and EL become more active, leading to more rapid hydrolysis and clearance of triglyceride-rich lipoproteins (like VLDL and chylomicrons) and overall increased lipid metabolism. This heightened processing of fats in the blood is the key effect. Because of this enhanced lipolysis, you don’t see a rise in LDL-C; in fact, LDL-C often falls with ANGPTL3 inhibition. HDL changes are not the primary outcome here, and glucose levels aren’t directly affected by this mechanism.

Inhibiting ANGPTL3 releases the brakes on lipid breakdown by lipoprotein lipase (LPL) and endothelial lipase (EL). Evinacumab blocks ANGPTL3, so LPL and EL become more active, leading to more rapid hydrolysis and clearance of triglyceride-rich lipoproteins (like VLDL and chylomicrons) and overall increased lipid metabolism. This heightened processing of fats in the blood is the key effect.

Because of this enhanced lipolysis, you don’t see a rise in LDL-C; in fact, LDL-C often falls with ANGPTL3 inhibition. HDL changes are not the primary outcome here, and glucose levels aren’t directly affected by this mechanism.

More practice questions